News | Chronic Total Occlusion (CTO) | June 28, 2017

Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter

Intravascular ultrasound helps physicians decide, guide, treat and confirm true lumen re-entry with speed and precision

Philips Announces Relaunch of Pioneer Plus IVUS-Guided Catheter

June 28, 2017 — Royal Philips recently announced the relaunch of its Pioneer Plus catheter, the first and only re-entry device with intravascular ultrasound (IVUS) capabilities and needle deployment designed to assist arterial vessel intervention. IVUS captures images of vessels in the peripheral vascular system from inside the artery, allowing physicians to identify a targeted area and place a catheter in a specific location and to help guide the treatment partially or fully blocked arteries.

“The Pioneer Plus catheter is an invaluable medical device that benefits both physicians and patients,” said Thomas Davis, M.D., director of the cardiac catheter lab at St. John Hospital and Medical Center in Detroit.  “This catheter can decrease procedure time, which can potentially minimize the patients’ discomfort because they spend less time on the operating table.”

The Pioneer Plus catheter is intended to facilitate placement and positioning of catheters within the peripheral vasculature. Commonly used to help treat chronic total occlusions (CTOs), which are caused by heavy build-up of plaque within an artery that can cause blockages, Pioneer Plus enables a physician to cross the occlusion beyond the stenotic lesion prior to additional interventional treatment of the lesion using interventional techniques. With a successful interventional procedure, patients may avoid having surgery, which is a considerable improvement in patient care and outcomes as CTOs patients are often at risk for amputation.

The device also provides a cross-sectional ultrasound image of the arterial area of interest to facilitate placement of guidewires beyond stenotic lesions (e.g., sub-total, total or chronic total occlusions) prior to additional interventions (i.e. PTA, stent, etc.). According to a study published by the Journal of Invasive Cardiology, the Pioneer Plus catheter demonstrated a 95-100 percent procedural success rate in procedures affecting the arterial wall, specifically subintimal angioplasty. The study found a rate of 26 percent of failed re-entry for cases of CTO that did not use the Pioneer Plus catheter.1

Philips initiated a design modification to the Pioneer Plus catheter in 2015, and proactively removed the device from the market until the modification was complete. The design modification has had no impact to the overall catheter dimensions, performance or the intended use of the device.

Pioneer Plus has received U.S. Food and Drug Administration (FDA) clearance and CE mark approval. The device is not indicated for use in the coronary or cerebral vasculature. 

For more information: www.usa.philips.com/healthcare

Related Content

Nuance Communications Inc. introduced Nuance Cardiovascular CAPD, a new computer-assisted physician documentation (CAPD) solution designed to help cardiologists improve the quality of complex documentation and the accuracy of reimbursement for cardiac catheterization procedures. The Nuance Cardiovascular CAPD solution is available through a partnership with ZHealth for this solution, which is based on patented algorithms built with ZHealth’s interventional documentation and coding expertise.
News | Cath Lab | January 31, 2020
January 29, 2020 – Nuance Communications Inc.
Videos | Cath Lab | January 09, 2020
Haval Chweich, M.D., medical director of the cardiac critical care unit (CCU) at Tufts Medical Center, and assistant...
People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.  In early December 2019, leaders of the European Association for Cardiothoracic Surgery (EACTS) withdrew their support for European practice guidelines that endorse the use of coronary stents in many patients with left main coronary artery disease.

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes.

News | Cath Lab | January 02, 2020 | Dave Fornell, Editor
January 2, 2020 — In early December 2019, leaders of the European As...
News | Cath Lab | December 18, 2019
December 18, 2019 — Cook Medical initiated a recall of its CrossCath Support Catheters in November, which the U.S.
Gallery | Cath Lab | October 31, 2019 | Dave Fornell, Editor
This is a photo essay of the interventional cardiology and structural heart technologies on the expo floor and discus
The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

The Alphenix Aero Package from Canon Medical Systems USA, Inc. enables OBLs and ASCs to attain premium technology at a flexible price point by tailoring Canon Medical’s Alphenix systems to fit their facilities’ needs.

Technology | Cath Lab | October 28, 2019
Office based labs (OBLs) and ambulatory surgery centers (ASCs) require a fresh perspective from imaging vendors.
Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

Marco Costa, M.D., Ph.D., MBA, president, UH Harrington Heart and Vascular Institute, performing a cath lab procedure.

News | Cath Lab | October 28, 2019
October 28, 2019 — Leaders within University Hospitals and the Harrington Heart and Vascular Institute had a vision t
OmniVision Announces Guinness World Record for Smallest Image Sensor

OmniVision's OVM6948 CameraCubeChip, a fully packaged, wafer-level camera module measuring 0.65mm x 0.65mm x 1.158mm, built on OmniVision's OV6948, winner of the Guinness World Record for “The Smallest Image Sensor Commercially Available.”

News | Cath Lab | October 22, 2019
October 22, 2019 — OmniVision Technologies Inc.
People watch the presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., live in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long term surgical outcomes. #TCT2019

People watch the live presentation of the five-year EXCEL Trial data by Gregg Stone, M.D., in the Abbott booth at TCT 2019. Abbott makes the Xience stent used in the trial, which compared equally with long-term CABG surgical outcomes. 

Feature | Cath Lab | October 03, 2019
October 3, 2019 – Five-year data from the EXCEL Trial showed patients with left main coronary disease treated with pe
Overlay Init